Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) was the target of a significant growth in short interest during the month of August. As of August 31st, there was short interest totalling 2,492,906 shares, a growth of 39.2% from the August 15th total of 1,790,242 shares. Approximately 4.3% of the company’s shares are sold short. Based on an average daily volume of 533,555 shares, the short-interest ratio is currently 4.7 days.

Several equities analysts have recently commented on JAZZ shares. Wells Fargo & Company reaffirmed an “outperform” rating and set a $177.00 price objective (down from $178.00) on shares of Jazz Pharmaceuticals PLC in a research note on Thursday, August 10th. BidaskClub downgraded shares of Jazz Pharmaceuticals PLC from a “hold” rating to a “sell” rating in a research note on Thursday, August 3rd. Vetr raised shares of Jazz Pharmaceuticals PLC from a “hold” rating to a “buy” rating and set a $151.11 price objective for the company in a research note on Tuesday, June 6th. Piper Jaffray Companies reaffirmed an “overweight” rating and set a $182.00 price objective on shares of Jazz Pharmaceuticals PLC in a research note on Wednesday, June 7th. Finally, Cowen and Company reaffirmed an “outperform” rating and set a $190.00 price objective on shares of Jazz Pharmaceuticals PLC in a research note on Wednesday, June 7th. One analyst has rated the stock with a sell rating, three have issued a hold rating and nineteen have issued a buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average price target of $180.96.

Shares of Jazz Pharmaceuticals PLC (NASDAQ JAZZ) opened at 151.48 on Friday. The firm has a 50-day moving average of $149.01 and a 200-day moving average of $150.05. Jazz Pharmaceuticals PLC has a one year low of $95.80 and a one year high of $163.75. The stock has a market cap of $9.10 billion, a PE ratio of 23.33 and a beta of 1.13.

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) last posted its quarterly earnings results on Tuesday, August 8th. The specialty pharmaceutical company reported $1.72 EPS for the quarter, missing the consensus estimate of $1.85 by ($0.13). Jazz Pharmaceuticals PLC had a net margin of 25.69% and a return on equity of 22.75%. The business had revenue of $394.39 million during the quarter, compared to the consensus estimate of $410.83 million. During the same quarter in the prior year, the firm posted $2.67 EPS. The company’s revenue for the quarter was up 3.5% compared to the same quarter last year. On average, equities research analysts expect that Jazz Pharmaceuticals PLC will post $10.89 earnings per share for the current fiscal year.

In other news, EVP Suzanne Sawochka Hooper sold 420 shares of the company’s stock in a transaction dated Friday, June 23rd. The shares were sold at an average price of $160.00, for a total transaction of $67,200.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Bruce C. Cozadd sold 1,000 shares of the company’s stock in a transaction dated Tuesday, September 12th. The shares were sold at an average price of $153.52, for a total transaction of $153,520.00. The disclosure for this sale can be found here. Insiders sold 8,717 shares of company stock valued at $1,346,617 over the last three months. 4.30% of the stock is currently owned by insiders.

Several large investors have recently bought and sold shares of the company. Intl Fcstone Inc. bought a new stake in shares of Jazz Pharmaceuticals PLC in the 2nd quarter valued at about $230,000. Toronto Dominion Bank raised its holdings in shares of Jazz Pharmaceuticals PLC by 12.4% in the 2nd quarter. Toronto Dominion Bank now owns 736 shares of the specialty pharmaceutical company’s stock valued at $114,000 after purchasing an additional 81 shares in the last quarter. WINTON GROUP Ltd bought a new stake in shares of Jazz Pharmaceuticals PLC in the 2nd quarter valued at about $433,000. GRATRY & Co LLC raised its holdings in shares of Jazz Pharmaceuticals PLC by 121.6% in the 2nd quarter. GRATRY & Co LLC now owns 17,040 shares of the specialty pharmaceutical company’s stock valued at $2,650,000 after purchasing an additional 9,350 shares in the last quarter. Finally, Verition Fund Management LLC bought a new stake in shares of Jazz Pharmaceuticals PLC in the 2nd quarter valued at about $1,959,000. Institutional investors and hedge funds own 88.24% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Short Interest in Jazz Pharmaceuticals PLC (JAZZ) Rises By 39.2%” was originally reported by American Banking News and is owned by of American Banking News. If you are reading this report on another domain, it was stolen and republished in violation of U.S. and international copyright & trademark law. The original version of this report can be accessed at https://www.americanbankingnews.com/2017/09/16/short-interest-in-jazz-pharmaceuticals-plc-jazz-rises-by-39-2.html.

About Jazz Pharmaceuticals PLC

Jazz Pharmaceuticals, Inc is a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry. As of December 31, 2009, the Company markets two products: Xyrem (sodium oxybate) for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy; and Luvox CR (fluvoxamine maleate) for the treatment of both obsessive compulsive disorder and social anxiety disorder.

Receive News & Ratings for Jazz Pharmaceuticals PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals PLC and related companies with MarketBeat.com's FREE daily email newsletter.